| 翻訳と辞書 |
| Anidulafungin ： ウィキペディア英語版 |
Anidulafungin
Anidulafungin (brand names: Eraxis (in U.S. and Russia), Ecalta (in Europe)) is a semisynthetic echinocandin used as an antifungal drug. Anidulafungin was originally manufactured and submitted for FDA approval by Vicuron Pharmaceuticals.〔PRNewswire. (Vicuron Pharmaceuticals Files New Drug Application (NDA) for Anidulafungin for Treatment of Invasive Candidiasis/Candidemia ) 08-18-2005.〕 Pfizer acquired the drug upon its acquisition of Vicuron in the fall of 2005.〔PRNewswire. (Vicuron Pharmaceuticals Stockholders Approve Merger With Pfizer ) 08-15-2005〕 Pfizer gained approval by the Food and Drug Administration (FDA) on February 21, 2006; it was previously known as LY303366. Preliminary evidence indicates it has a similar safety profile to caspofungin. Anidulafungin has proven efficacy against esophageal candidiasis, but its main use will probably be in invasive ''Candida'' infection; it may also have application in treating invasive ''Aspergillus'' infection. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)-β-D-glucan synthase, an enzyme important to the synthesis of the fungal cell wall.
==Pharmacodynamics and pharmacokinetics==
Anidulafungin significantly differs from other antifungals in that it undergoes chemical degradation to inactive forms at body pH and temperature. Because it does not rely on enzymatic degradation or hepatic or renal excretion, the drug is safe to use in patients with any degree of hepatic or renal impairment.〔(【引用サイトリンク】url=http://www.rxlist.com/eraxis-drug.htm#cp )〕
Distribution: 30–50 L. Protein binding: 84%.
Anidulafungin is evidently metabolized by the liver. This specific drug undergoes slow chemical hydrolysis to an open-ring peptide which lacks antifungal activity. The half-life of the drug is 27 hours. Thirty percent is excreted in the feces (10% as unchanged drug). Less than 1% is excreted in the urine.〔Trissel LA and Ogundele AB, "Compatibility of Anidulafungin With Other Drugs During Simulated Y-Site Administration,"Am J Health-Sys Pharm, 2005, 62:834-7.〕〔Vazquez JA, "Anidulafungin: A New Echinocandin With a Novel Profile," Clin Ther, 2005, 27(6):657-73.〕〔Walsh TJ, Anaissie EJ, Denning DW, et al, "Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America," ''Clin Infect Dis'', 2008, 46(3):327-60〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Anidulafungin」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|